Modulation of claudin-1 expression by ∆2-TGZ in triple negative breast cancer cells is correlated to apoptosis - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2018

Modulation of claudin-1 expression by ∆2-TGZ in triple negative breast cancer cells is correlated to apoptosis

Résumé

Breast cancer represents the first lethal malignancy across the world in women. Innate and acquired resistances are the leading causes of therapeutic failure. Furthermore, 76% of triple negative tumors (ER-, PR- and HER2-) do not express any more claudin 1, a major constituent of tight junctions. Patients with these “claudin 1-low” triple negative tumors present a high relapse incidence. A major challenge in oncology is the development of innovative therapies for these poor prognosis tumors. In this context, our laboratory synthetized a promising compound derived from troglitazone (TGZ), Δ2-TGZ, which presents a higher antiproliferative activity and a lower hepatic toxicity than its parental compound. In this study, we showed that 1) Δ2-TGZ induces claudin 1 expression and apoptosis in triple negative breast cancer cells but not in non-tumorigenic mammary cells; 2) Claudin 1 overexpression leads to a pro-apoptotic effect in triple negative MDA-MB-231 and Hs578T cells and 3) Claudin 1 knockdown prevents Δ2-TGZ-induced apoptotic effect in triple negative MDA-MB-231 cells. In fine, our study suggests that the strategy of claudin-1 re-expression could be a promising therapeutic option for the aggressive “claudin 1-low” triple negative tumors.
Fichier non déposé

Dates et versions

hal-01947874 , version 1 (07-12-2018)

Identifiants

  • HAL Id : hal-01947874 , version 1

Citer

Marine Geoffroy, Alexandra Kleinclauss, Michel Boisbrun, Marine Lemesle, Stéphane Flament, et al.. Modulation of claudin-1 expression by ∆2-TGZ in triple negative breast cancer cells is correlated to apoptosis. 20th World Congress of Senologic International Society on Breast HealthCare, Dec 2018, Strasbourg, France. ⟨hal-01947874⟩
50 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More